📊 ORGO Key Takeaways
Is Organogenesis Holdings Inc. (ORGO) a Good Investment?
Organogenesis demonstrates strong revenue growth (17% YoY) and exceptional net income acceleration (85% YoY) supported by a fortress balance sheet with 3.62x current ratio and conservative 0.21x leverage. However, the company faces a critical earnings quality concern: negative operating cash flow of -$10.3M and negative free cash flow of -$24.5M despite $37M reported net income, indicating working capital deterioration that undermines sustainability.
Why Buy Organogenesis Holdings Inc. Stock? ORGO Key Strengths
- Strong revenue growth of 17% YoY with accelerating net income growth of 85% demonstrating operating leverage improvements
- Exceptional liquidity position with current ratio of 3.62x, quick ratio of 3.32x, and $93.7M cash reserves providing financial flexibility
- Conservative capital structure with debt-to-equity of 0.21x and exceptional interest coverage of 39.4x reducing financial risk
ORGO Stock Risks: Organogenesis Holdings Inc. Investment Risks
- Critical: Negative operating cash flow (-$10.3M) and negative free cash flow (-$24.5M) despite profitability signals severe earnings quality issues and potential accrual manipulation
- Extremely thin margins with gross margin of 11.2% and operating margin of 7.9% creating vulnerability to cost pressures or volume declines
- Working capital deterioration and cash conversion failure suggest unsustainable business model that cannot fund growth organically despite balance sheet strength
Key Metrics to Watch
- Operating cash flow trend - must demonstrate immediate improvement to next quarter positive to restore credibility
- Days Sales Outstanding, inventory levels, and accounts payable changes - identify root cause of working capital drain
- Free cash flow conversion - validate that net income growth can translate to sustainable cash generation
Organogenesis Holdings Inc. (ORGO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.62x current ratio provides a solid financial cushion.
ORGO Profit Margin, ROE & Profitability Analysis
ORGO vs Healthcare Sector: How Organogenesis Holdings Inc. Compares
How Organogenesis Holdings Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Organogenesis Holdings Inc. Stock Overvalued? ORGO Valuation Analysis 2026
Based on fundamental analysis, Organogenesis Holdings Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Organogenesis Holdings Inc. Balance Sheet: ORGO Debt, Cash & Liquidity
ORGO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Organogenesis Holdings Inc.'s revenue has grown significantly by 21% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.04 reflects profitable operations.
ORGO Revenue Growth, EPS Growth & YoY Performance
ORGO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $115.2M | -$6.7M | $-0.05 |
| Q2 2025 | $101.0M | -$9.4M | $-0.10 |
| Q1 2025 | $86.7M | -$2.1M | $-0.02 |
| Q3 2024 | $108.5M | $3.2M | $0.02 |
| Q2 2024 | $117.3M | $2.3M | $0.02 |
| Q1 2024 | $107.6M | -$2.1M | $-0.02 |
| Q3 2023 | $108.5M | $215.0K | $0.00 |
| Q2 2023 | $117.3M | $2.3M | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Organogenesis Holdings Inc. Dividends, Buybacks & Capital Allocation
ORGO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Organogenesis Holdings Inc. (CIK: 0001661181)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ORGO
What is the AI rating for ORGO?
Organogenesis Holdings Inc. (ORGO) has an AI rating of HOLD with 58% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ORGO's key strengths?
Claude: Strong revenue growth of 17% YoY with accelerating net income growth of 85% demonstrating operating leverage improvements. Exceptional liquidity position with current ratio of 3.62x, quick ratio of 3.32x, and $93.7M cash reserves providing financial flexibility.
What are the risks of investing in ORGO?
Claude: Critical: Negative operating cash flow (-$10.3M) and negative free cash flow (-$24.5M) despite profitability signals severe earnings quality issues and potential accrual manipulation. Extremely thin margins with gross margin of 11.2% and operating margin of 7.9% creating vulnerability to cost pressures or volume declines.
What is ORGO's revenue and growth?
Organogenesis Holdings Inc. reported revenue of $564.2M.
Does ORGO pay dividends?
Organogenesis Holdings Inc. does not currently pay dividends.
Where can I find ORGO SEC filings?
Official SEC filings for Organogenesis Holdings Inc. (CIK: 0001661181) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ORGO's EPS?
Organogenesis Holdings Inc. has a diluted EPS of $0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ORGO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Organogenesis Holdings Inc. has a HOLD rating with 58% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ORGO stock overvalued or undervalued?
Valuation metrics for ORGO: ROE of 12.3% (sector avg: 15%), net margin of 6.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ORGO stock in 2026?
Our dual AI analysis gives Organogenesis Holdings Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ORGO's free cash flow?
Organogenesis Holdings Inc.'s operating cash flow is $-10.3M, with capital expenditures of $14.2M. FCF margin is -4.3%.
How does ORGO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.6% (avg: 12%), ROE 12.3% (avg: 15%), current ratio 3.62 (avg: 2).